Vinge advised Xspray Pharma on the deal. Xspray Pharma AB (publ) completed a rights issue of shares whereby Xspray receives issue proceeds of approximately SEK 135...
Xspray Pharma’s Rights Offering
Egetis Therapeutics’ Shares Offering
Vinge advised Egetis Therapeutics on the deal. Egetis Therapeutics AB (publ), listed on Nasdaq Stockholm, completed a directed share issuances whereby Egetis Therapeutics receives gross proceeds...
Cinclus Pharma’s Listing on Nasdaq Stockholm
Vinge advised Cinclus Pharma on the deal. Cinclus Pharma Holding AB (publ) secured an offering of new ordinary shares and listing on Nasdaq Stockholm. The offering...
Asahi Kasei Corporation’s Public Takeover Offer Agreement with Calliditas Therapeutics
Vinge advised Calliditas Therapeutics on the deal. Asahi Kasei Corporation announced a public takeover offer to the shareholders and holders of American Depositary Shares in Calliditas...
Episurf Medical’s Rights Offering
Vinge advised Pareto Securities on the offering. Episurf Medical secured rights issue of units of up to approximately SEK 120 million. Episurf Medical is a Swedish,...
Hansa Biopharma’s Shares Offering
Vinge advised Hansa Biopharma AB on the deal. Hansa Biopharma AB (publ) finalized a directed share issue through which the company raises proceeds of SEK 372 million...
Oncopeptides AB’s Rights Offering
Vinge advised Oncopeptides AB on the deal. Oncopeptides AB (publ) finalized a fully guaranteed rights issuance which will provide Oncopeptides with issue proceeds of approximately SEK...
Vimian Group’s Rights Offering
Vinge advised Vimian Group AB on the offering. Vimian Group AB (publ) partly guaranteed rights issue which will provide Vimian with issue proceeds of SEK 1,633...
Precio Fishbone’s Sale of Shares in a Subsidiary Company
Vinge advised Precio Fishbone AB on the deal. Precio Fishbone AB (publ) completed the sale of approximately 80.1 per cent of the shares in the subsidiary...
Cell Impact’s Rights Offering
Vinge advised Cell Impact AB on the deal. Cell Impact AB (publ) completed a rights issuance which will provide Cell Impact with issue proceeds of SEK 129...
Egetis Therapeutics AB’s Equity Private Placement and Debt Financing
Vinge advised Egetis Therapeutics AB on the deal. Egetis Therapeutics AB (publ), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization...
Xspray Pharma’s SEK 300 Million Rights Issuance
Vinge acted for Xspray Pharma in connection with its rights issue of units. Through the rights issue of units, Xspray (STO:XSPRAY) is expected to receive approximately SEK 300...